A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Diabetic Macular Edema

Interventions

DRUG

Teprotumumab

Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions

Trial Locations (3)

David A Eichenbaum, MD, St. Petersburg

Diana Do, MD, Omaha

David S Boyer, Beverly Hills